Skip to main content

Table 1 Demographic data

From: Perioperative patient-specific factors-based nomograms predict short-term periprosthetic bone loss after total hip arthroplasty

Variables Prevalence or average
Age (years) 59.3 ± 10.8
Male 45.7% (195/427)
Married 94.1% (402/427)
BMI (kg/m2) 23.4 ± 3.8
Current/former smoker 39.6% (169/427)
Comorbidities
 Diabetes mellitus 17.3% (74/427)
 Hypertension 36.3% (155/427)
 Stroke 6.8% (29/427)
 Heart dysfunction 8.7% (37/427)
 Othersa 17.1% (73/427)
Diagnosis
 Femoral neck fracture 22.7% (97/427)
 Femoral head necrosis 49.6% (212/427)
 Hip osteoarthritis 17.8% (76/427)
 Developmental dysplasia of the hip 9.8% (42/427)
History of anti-osteoporosis therapy in the last year 20.4% (87/427)
Preoperative systematic BMD
 Spine (g/cm2) 0.881 ± 0.150
 Hip (g/cm2) 0.828 ± 0.181
Serum ALP (U/L) 74.9 ± 25.6
Serum calcium (mmol/L) 2.31 ± 0.12
Preoperative Harris score of the involved hip 41.7 ± 19.9
Femoral component design
 Straight stem 65.1% (278/427)
 Anatomic stem 34.9% (149/427)
  1. aindicated other comorbidities including chronic obstructive pulmonary disease, pulmonary infection, dementia, Parkinson’s disease, digestive system disorders, and chronic renal failure